By Colin Kellaher
MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera Therapeutics for an initial $40 million.
MacroGenics on Tuesday said it is eligible to receive up to $35 million in additional sales milestone payments as part of the deal, which is slated to close by the end of the year.
The Rockville, Md., company said the transaction will let it focus on advancing its pipeline of oncology product candidates.
MacroGenics launched Margenza, its first commercial product, in 2021. In its annual report for 2023, MacroGenics said Margenza hadn't generated enough revenue to be profitable, and the company warned that the drug may never achieve or sustain profitability.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2024 07:53 ET (11:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。